Business
Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show
The Eli Lilly and Novo Nordisk logos.
Mike Blake | Tom Little | Reuters
It’s a tale of two drugmakers in the red-hot obesity drug market.
Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, Lilly sees revenue jumping again thanks to its blockbuster medicines.
The split in guidance — despite similar headwinds — underscores the strength of Lilly’s position in the obesity and diabetes drug market, underpinned by its more effective injections and early foray into direct-to-consumer sales, among other factors. While Novo Nordisk effectively made the drugs mainstream, Lilly has since taken a clear edge in market share — and the forecasts show it will likely only extend its advantage this year.
“The difference in sales momentum and market share trend was visible throughout 2025, but the dichotomy between the two companies’ prospects was accentuated within this 24-hour period in which Novo guided below consensus and Lilly guided above consensus expectations,” Leerink Partners analyst David Risinger told CNBC on Wednesday.
“That really solidified an investor’s mind that Lilly is going to be the dominant player in obesity going forward,” he added.
This year, all eyes will be on how Lilly’s upcoming obesity pill, orforglipron, fares against Novo’s own oral Wegovy drug, which has had an explosive U.S. launch this year.
In an interview on CNBC’s “Squawk Box” on Wednesday, Lilly CEO David Ricks said 20 million to 25 million patients are currently taking both companies’ medicines. But he said the total addressable market of patients in the obesity space is “gigantic.”

Diverging outlooks
On Wednesday, Lilly forecasted 2026 sales of $80 billion to $83 billion, surpassing the $77.62 billion that analysts were expecting, according to LSEG.
The midpoint of that outlook translates to sales growing by 25% this year.
In contrast, Novo warned on Tuesday that it sees sales and profit declining by 5% to 13% this year, as prices fall in the U.S. and exclusivity expires for its blockbuster obesity and diabetes drugs in China, Brazil and Canada.
Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, listen as President Donald Trump speaks in the Oval Office during an event about weight-loss drugs on Nov. 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Images
Lilly similarly pointed to a “global pricing decline in the low- to mid- teens [percentages] this year.” That comes after the landmark “most favored nation” deals both companies struck with President Donald Trump in November to slash obesity and diabetes drug costs, along with their recent efforts to further reduce direct-to-consumer prices for their treatments.
The agreements with Trump are expected to take a bite out of both companies’ sales, but eventually increase volumes of prescriptions for their drugs. Still, Lilly is bullish about other factors that will help offset that pricing pressure.
That includes continued worldwide demand for its obesity drug Zepbound and diabetes counterpart Mounjaro and the expected launch of its GLP-1 pill for obesity in the second quarter, pending U.S. approval. Lilly also pointed to government Medicare coverage of obesity treatments starting for the first time by at least July, one of the winning features of the drug pricing deals with Trump.
Lilly’s Ricks told CNBC that coverage will open up access to 40 million new Medicare beneficiaries, “and that could be quite expansive to volume.”
Overall, Risinger called Lilly’s guidance “very encouraging” and said the “price per volume trade-off is playing out well” for the company.
He said tirzepatide, the active ingredient in Zepbound and Mounjaro, is “superior” in its effectiveness and tolerability compared to semaglutide, the ingredient in Novo’s obesity and diabetes drugs. That was proven in a head-to-head clinical trial conducted by Lilly in 2024, and prescription trends show that the company’s drugs are preferred among prescribers.
“I think that’s what is driving Lilly’s market share gain” relative to Novo, Risinger said.
Another factor that sets Lilly and Novo apart is patent exclusivity. While Novo said expiring patents in some international markets pose a challenge, Lilly’s Ricks said tirzepatide should be protected into “the back half of the 2030s” in major markets.
Risinger noted that Lilly is still working to drive global uptake for tirzepatide, which won U.S. approval for obesity in 2023.
All eyes on pills
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.
George Frey | Bloomberg | Getty Images
Novo Nordisk is first to market with a GLP-1 pill for obesity, and it hit 50,000 weekly prescriptions in just under three weeks of its launch. But investors are watching to see how that shifts once Lilly’s pill rolls out to patients later this year.
In an interview with CNBC’s “Mad Money,” Novo CEO Mike Doustdar said he’s confident about the company’s ability to compete with Lilly.
“Clearly we have the most efficacious weight-reduction pill that there is and I’m very optimistic and bullish on when they come with their pill and we have to battle this out,” Doustdar said.
He’s referring to clinical trial data suggesting that Novo’s Wegovy pill promotes comparable weight loss to its injectable counterpart, which is around 15%. Meanwhile, Lilly’s pill appears to be slightly less effective than that, based on separate study data.
Risinger said the launch of Novo’s pill has benefited from the fact that the company is leveraging the Wegovy brand name, which is recognizable by many patients, and immediately launched direct-to-consumer advertising for the product in early January.
But he said Lilly could capitalize on its pill’s convenience advantage.
Orforglipron is a small-molecule drug that is absorbed more easily in the body and doesn’t require dietary restrictions like Novo Nordisk’s pill, which is a peptide medication. Patients are supposed to drink no more than four ounces of water with the Wegovy pill and must wait 30 minutes before eating or drinking anything else each day.
Novo contends that those requirements won’t hinder uptake, but Risinger said it could help Lilly’s pill eventually generate greater sales globally.
Business
CreditBlockchain Strengthens Digital Infrastructure Through Advanced Cloud Solutions

CreditBlockchain Strengthens Digital Infrastructure Through Advanced Cloud Solutions
Business
Plan to advance conservative playbook
Efforts to undermine support for the Albanese government in WA focus on issues including net zero, immigration and welcome to country.
Business
Sebi to ease ‘fit and proper person’ criteria
The regulator has suggested to remove automatic disqualification of individuals holding key positions on filing of an FIR (first information report) or a charge sheet in economic offence cases.
“It has been represented that mere pendency of criminal complaint or FIR or filing of charge sheet should not trigger disqualification, as filing of such criminal complaint or FIR or charge sheet are the preliminary steps to set the criminal law into motion. The same is also stated to be against the settled principle of criminal law that all persons are innocent until proven guilty,” Sebi said in a discussion paper on Wednesday.
The move comes after the regulator submitted before the Bombay High Court that it would review its rules on ‘fit on proper person’ after brokers involved in the National Spot Exchange (NSEL) case, including Anand Rathi Commodities and Motilal Oswal, challenged a Sebi order declaring them ‘not fit and proper’ to operate.
These brokers argued that disqualification merely on allegations was a violation of their constitutional rights.
As per current rules, intermediaries, key managerial personnel and persons in control incur a disqualification if there is a pending criminal complaint or FIR filed by Sebi or a pending charge sheet concerning economic offences by an enforcement agency.
The regulator has now proposed that a rule-based formula may be onerous and not appropriate as it could lead to unintended consequences such as putting a person at a disadvantageous position at a preliminary stage of pending criminal complaint or charge sheet, which could later result in acquittal or discharge.This may also be counterproductive to the objective of promoting ease of doing business, it said.
Any serious or incriminating factor may be taken into account on a case-to-case basis in the context of the person’s overall conduct and the potential risk to the interests of the investors, Sebi said.
The regulator said it would come out with guidelines regarding cases where pendency of criminal proceedings is egregious enough to incur disqualification.
Business
QUALCOMM Incorporated 2026 Q1 – Results – Earnings Call Presentation (NASDAQ:QCOM) 2026-02-04
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Business
Chrysler recalls 450,000 vehicles over light brake failure safety risk concern
Check out what’s clicking on FoxBusiness.com.
Chrysler is recalling more than 450,000 vehicles and more than 2,000 tow-trailer modules over a light brake failure that could raise the risk of a crash, according to the National Highway Traffic Safety Administration (NHTSA).
The recall impacts 456,287 vehicles and an additional 2,871 tow-trailer modules, the NHTSA said in a pair of notices on Monday.
The affected vehicles contain the faulty modules, which the agency said were improperly designed.
TOYOTA RECALLS 161K TUNDRA TRUCKS OVER REARVIEW CAMERA DEFECT THAT INCREASES CRASH RISK

Chrysler is recalling more than 450,000 vehicles and more than 2,000 tow-trailer modules over a light brake failure. (Bing Guan/Bloomberg via Getty Images / Getty Images)
The modules impacted by the recall may result in the brake lights on attached trailers failing to illuminate, or they may cause trailer brakes to fail altogether, cutting visibility and increasing crash risk.
The impacted products include the 2026 Jeep Cherokee, 2024-2026 Jeep Wagoneer S, 2025-2026 Ram 1500, 2025-2026 Ram 2500, 2025-2026 Ram 3500, 2025-2026 Ram 4500, 2025-2026 Ram 5500 and certain Mopar tow-trailer modules.

The affected vehicles contain the faulty modules, which were improperly designed. (Graham Hughes/Bloomberg via Getty Images / Getty Images)
Anyone with the recalled tow-trailer modules installed can take them to their Fiat Chrysler Automobiles dealer for a free replacement. If the module is not installed, dealers will repurchase the item.
If the tow-trailer module is installed in a vehicle, dealers will replace it for free. If the tow-trailer module is not installed in a vehicle, dealers will repurchase it.
TOYOTA RECALLS ABOUT 127K PICKUP TRUCKS, SUVS OVER POTENTIAL ENGINE ISSUES

The modules impacted by the recall may result in the brake lights on attached trailers failing to illuminate, or they may cause trailer brakes to fail altogether, cutting visibility and increasing crash risk. (Getty Images / Getty Images)
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Owners of recalled vehicles that come with the module installed can take them to their Fiat Chrysler Automobiles dealer for a free replacement.
Owner notification letters will be sent out on March 24, 2026.
Business
CBD skyscraper to become hotel
After years of speculation, a $250 million plan to overhaul the Kuwait government-owned St Martins Tower has finally been revealed.
Business
Gold, Silver Prices Surge to Reignite Rally. Why They’re Rebounding After Selloff.
Gold, Silver Prices Surge to Reignite Rally. Why They’re Rebounding After Selloff.
Business
No immediate steps planned to regulate equity derivatives: Tuhin Kanta Pandey
“At this moment, we are not contemplating any measures, and whatever framework that we have put in place, that will continue,” Pandey said. “When we as a regulator look at derivative markets, we do so in a very methodical manner based on data.”
The government raised transaction taxes on equity derivatives in the Union Budget to curb speculative trading. India’s futures and options volumes are more than 500 times the country’s GDP, underscoring the need for arate adjustment to rein in excessive activity, it said.
Separately, on the US-India trade deal, he said it would help get more investments into the country.
“Fundamentally, when you have an overhang of a regulatory action which is removed, and trade frictions removed, capital formation is always accelerated,” Pandey said. He added that the removal of the uncertainties can spur investment decisions and get a greater predictability on capital. “So overall in the situation I could say that with the deals that have been done on the trade side, a lot of uncertainties have been removed,” he said.
Algo Trades may Soon Not Face OTR Penalties
The Securities and Exchange Board of India (Sebi) on Wednesday proposed changes to its order-to-trade ratio (OTR) framework for equity options, to exempt algorithmic orders placed by market makers from OTR penalties.
Under the revised framework, for equity option contracts, orders placed within a range of 40% above or below the last traded price (premium) “or ± ₹20, whichever is higher, shall be exempted from the framework for imposing penalty for high OTR,” the regulator said in a circular.At present, stock exchanges place economic disincentive for high order-to-trade ratio of algorithmic orders placed by stockbrokers. Further, algorithmic orders placed by designated market makers for market making activity would not be considered towards computation of OTR, Sebi said. “Orders placed within the range of ±0.75% of the LTP shall be exempted from the framework for imposing penalty for high OTR,” it said
No Fresh Curbs on Equity Derivatives
Pandey was speaking at the launch of a corporate-bond outreach event, where he noted that measures are being considered to deepen the bond market. Sebi will engage with market participants on implementing the Budget proposals related to corporate bonds, he said.
The recent Budget has proposed a series of reforms aimed at improving liquidity in the secondary market.
“A market-making framework will support continuous twoway quotes, reduce bid-ask spreads, and improve price discovery, thereby making corporate bonds a more reliable asset class for investors,” Pandey said. “Derivatives on corporate-bond indices and total-return swaps will help investors in efficient risk management. As secondary-market liquidity improves and investor base widens, the corporate-bond markets will become a more reliable and cheaper funding route for issuers.”
In FY25, issuers raised about ₹10 lakh crore through debt issuances. Outstanding corporate bonds have grown at roughly 12% CAGR, rising from ₹17.5 lakh crore in FY15 to ₹58 lakh crore by end-December 2025, according to Sebi data.
Pandey noted that the market remains heavily skewed towards highly rated issuers, who account for 90% of all bond issuances. Nearly 60% of funds are raised by financial institutions, limiting sectoral diversity.
“This concentration limits the choice available to investors and restricts fair price discovery across different sectors of the economy. The secondary market remains shallow because institutional investors follow a ‘buy-andhold’ approach rather than active trading,” he said.
This is further compounded by the dominance of private placements, which can reduce transparency and make it harder for smaller issuers to access the market, he added.
More than 5,600 companies are listed in the equity market, but only about 770 entities have raised funds through the debt market. Of these, 272 have tapped the market multiple times, while many have issued debt only once or twice, Sebi data showed.
He also said a Sebi survey showed that more Indians know about crypto currencies than about bonds.
Business
Motilal Oswal urges balanced portfolio mix as India-US trade deal lifts sentiment
“Investors could allocate 50% to large caps and hybrids, 40% to mid and small caps, and 10% to global markets,” says Ashish Shanker, MD & CEO, Motilal Oswal Private Wealth. He recommends making lumpsum allocations to large caps and hybrids immediately, while staggering investments into mid and small caps over the next couple of months. Within global markets, he favours emerging-market exposure.
Following the sharp run-up in silver prices, the wealth manager suggests partial profit-booking for investors with heavy exposure, while maintaining a neutral stance on gold for portfolio stability. Those under-allocated to gold can consider gradual accumulation on dips for ‘moderate’ medium-term returns.
Business
More drops for technology stocks weigh on Wall Street
More drops for technology stocks weighed on Wall Street Wednesday.
-
Crypto World6 days agoSmart energy pays enters the US market, targeting scalable financial infrastructure
-
Crypto World6 days ago
Software stocks enter bear market on AI disruption fear with ServiceNow plunging 10%
-
Politics5 days agoWhy is the NHS registering babies as ‘theybies’?
-
Crypto World6 days agoAdam Back says Liquid BTC is collateralized after dashboard problem
-
Video2 days agoWhen Money Enters #motivation #mindset #selfimprovement
-
Tech18 hours agoWikipedia volunteers spent years cataloging AI tells. Now there’s a plugin to avoid them.
-
Fashion5 days agoWeekend Open Thread – Corporette.com
-
NewsBeat6 days agoDonald Trump Criticises Keir Starmer Over China Discussions
-
Politics3 days agoSky News Presenter Criticises Lord Mandelson As Greedy And Duplicitous
-
Crypto World5 days agoU.S. government enters partial shutdown, here’s how it impacts bitcoin and ether
-
Sports4 days agoSinner battles Australian Open heat to enter last 16, injured Osaka pulls out
-
Crypto World4 days agoBitcoin Drops Below $80K, But New Buyers are Entering the Market
-
Crypto World3 days agoMarket Analysis: GBP/USD Retreats From Highs As EUR/GBP Enters Holding Pattern
-
Crypto World5 days agoKuCoin CEO on MiCA, Europe entering new era of compliance
-
Business5 days ago
Entergy declares quarterly dividend of $0.64 per share
-
Sports3 days agoShannon Birchard enters Canadian curling history with sixth Scotties title
-
NewsBeat2 days agoUS-brokered Russia-Ukraine talks are resuming this week
-
NewsBeat3 days agoGAME to close all standalone stores in the UK after it enters administration
-
Crypto World1 day agoRussia’s Largest Bitcoin Miner BitRiver Enters Bankruptcy Proceedings: Report
-
Crypto World6 days agoWhy AI Agents Will Replace DeFi Dashboards
